BND-67's dual mechanism of action enhanceseffector T-cell activity while reducing regulatory T-cell differentiation, aiming to restore effective anti-tumor immunity BND-67 的双重作用机制在增强效应 T 细胞活性的同时,减少调节性 T 细胞的分化,旨在恢复有效的抗肿瘤免疫反应。The BND-67 clinical program includes a lead-in BND-67 monotherapy followed by combination therapy with an anti–PD-1 agent, in patients who have relapsed following prior clinical benefit to immune checkpoint therapy BND-67 临床项目包括先进行 BND-67 单药导入治疗,随后联合抗 PD-1 药物进行治疗,适用于此前从免疫检查点治疗中获益但随后复发的患者。MISGAV, Israel 以色列米斯加夫, ,Nov. 9, 2026 2026年11月9日/PRNewswire/ -- /美通社/ --Biond Biologics Ltd. ('Biond' or the 'Company'), Biond Biologics Ltd.(“Biond”或“公司”),a private clinical-stage biopharmaceutical company developing first-in-class immunotherapies for cancer and immune-mediated diseases, today announced that the first patient has been dosed in a first-in-human Phase 1 dose escalation clinical trial in advanced solid tumors evaluating BND-67, a novel antibody-based therapy designed to prevent CD28 shedding.. 一家专注于开发针对癌症和免疫介导疾病的首创类免疫疗法的私营临床阶段生物制药公司今日宣布,在一项评估BND-67(一种旨在防止CD28脱落的新型抗体疗法)的晚期实体瘤首次人体I期剂量递增临床试验中,首位患者已接受给药。The first patient was treated at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of multiple clinical sites participating in the study. The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BND-67. 首位患者在以色列拉宾医学中心大卫杜夫癌症研究所接受了治疗,该研究所是参与本研究的多处临床试验中心之一。本试验旨在评估 BND-67 的安全性、耐受性、药代动力学、药效动力学以及初步抗肿瘤活性。The unique clinical design includes a lead-in BND-67 monotherapy treatment followed by combination therapy of BND-67 and anti-PD-1 therapy, in patients relapsing on anti-PD-1 therapy following prior clinical benefit, across selected oncology indications. The first patient completed BND-67 0.3 mg/kg monotherapy without any dose-limiting toxicities or infusion-related reactions and is now receiving BND-67 in combination with nivolumab once every two weeks (MOH_2026-04-14-015766).. 该独特的临床研究设计包括在选定肿瘤适应症中,对先前从抗PD-1治疗中获得临床获益但随后复发的患者,先进行BND-67单药导入治疗,随后给予BND-67与抗PD-1联合治疗。首位患者完成了0.3 mg/kg剂量的BND-67单药治疗,未出现任何剂量限制性毒性或输注相关反应,目前正每两周接受一次BND-67与纳武利尤单抗的联合治疗(MOH_2026-04-14-015766)。'Patients who relapse after responding to immunotherapy represent a significant unmet medical need. BND-67 is based on a compelling biological rationale and targets a previously unexplored mechanism of immune dysfunction like CD28 shedding,' said Professor Salomon Stemmer, M.D., Head of Research, Development and Innovation and Deputy Director of Davidoff Center at the Rabin Medical Center, Israel, and a clinical investigator in the trial. “对免疫治疗产生应答后复发的患者存在巨大的未满足医疗需求。BND-67 基于令人信服的生物学原理,靶向此前尚未探索的免疫功能障碍机制,如 CD28 脱落。”以色列拉宾医学中心大卫奥夫中心研究、开发与创新主管兼副主任、该试验的临床研究者 Salomon Stemmer 医学博士表示。'We are pleased to participate in this first-in-human study and investigate its potential to improve outcomes for patients with advanced solid tumors.'. “我们很高兴参与这项首次人体研究,并探讨其改善晚期实体瘤患者预后的潜力。”'BND-67 opens an entirely new therapeutic avenue for cancer immunotherapy,' said Giovanni Selvaggi, MD, Chief Medical Officer at Biond. 'CD28 has long been viewed as a cornerstone for T-cell activation, yet no targeted therapy has successfully harnessed it without compromising safety. By preventing CD28 shedding, BND-67 is designed to preserve physiological CD28 signaling and potentiate anti-tumor immune response, without the systemic toxicity associated with CD28 agonism. “BND-67 为癌症免疫治疗开辟了一条全新的治疗途径,”Biond 公司首席医疗官 Giovanni Selvaggi 医学博士表示。“CD28 长期以来被视为 T 细胞激活的基石,但尚无靶向疗法能够在不损害安全性的前提下成功利用它。通过阻止 CD28 脱落,BND-67 旨在维持生理性的 CD28 信号传导,增强抗肿瘤免疫反应,同时避免与 CD28 激动剂相关的全身毒性。”The BND-67 0.3 mg/kg was shown to be safe and tolerable with sustained receptor occupancy.' The Phase 1 lead-in design is intended to establish BND-67's initial safety and tolerability profile while assessing early signals of clinical activity.. BND-67在0.3 mg/kg剂量下显示出良好的安全性和耐受性,并具有持续的受体占有率。I期导入研究的设计旨在确立BND-67的初步安全性和耐受性特征,同时评估其早期临床活性信号。About BND-67 and CD28 Shedding 关于 BND-67 与 CD28 脱落BND-67 is a first-in-class immunotherapy designed to inhibit pathological CD28 shedding, an immune evasion mechanism found across many types of cancers first described by Biond. CD28 is a critical co-stimulatory receptor required for effective T-cell activation, proliferation, and persistence. In cancer patients, CD28 can be cleaved from the surface of T cells, by specific matrix metalloproteases (MMPs) that are secreted from various cells including T cells and from the cancer cells, leading to impaired immune responses and reduced sensitivity to immunotherapies.. BND-67 是一款首创的免疫疗法,旨在抑制病理性 CD28 脱落,这是一种由 Biond 首次描述的、在多种癌症中普遍存在的免疫逃逸机制。CD28 是一种关键的共刺激受体,为 T 细胞的有效激活、增殖和持久性所必需。在癌症患者中,特定的基质金属蛋白酶(MMPs)可将 CD28 从 T 细胞表面切割脱落;这些 MMPs 由包括 T 细胞在内的各种细胞以及癌细胞分泌,导致免疫反应受损,并降低对免疫疗法的敏感性。By preventing CD28 shedding, BND-67 is designed to enhance T-cell activation and expansion while selectively inhibiting regulatory T-cell differentiation and suppressive activity. Preclinical studies have demonstrated that BND-67 induces a potent and sustained anti-tumor immune response, both as a monotherapy and in combination with T-cell activating therapies including PD-1 inhibitors and T-cell engagers while demonstrating a favorable safety profile in animal models.. BND-67旨在通过阻止CD28脱落,在增强T细胞活化和扩增的同时,选择性抑制调节性T细胞的分化及其抑制活性。临床前研究表明,BND-67无论是作为单药治疗,还是与包括PD-1抑制剂和T细胞衔接器在内的T细胞活化疗法联合使用,均能诱导强效且持久的抗肿瘤免疫反应,并在动物模型中展现出良好的安全性特征。About Biond Biologics 关于 Biond BiologicsBiond Biologics is a private, clinical-stage biotechnology company developing first-in-class immunotherapies targeting novel pathways across both the innate and adaptive immune systems. The company's pipeline includes clinical-stage programs in oncology, alongside a growing portfolio of discovery and preclinical programs in immune-mediated diseases.. Biond Biologics 是一家私营的临床阶段生物技术公司,致力于开发针对先天性和适应性免疫系统中 novel 通路的首创类免疫疗法。公司的产品管线包括肿瘤学领域的临床阶段项目,以及不断增长的免疫介导疾病发现与临床前项目组合。Besides BND-67, Biond's clinical pipeline includes BND-22, a first-in-class antibody that acts as a multi-cell checkpoint inhibitor targeting the ILT2 receptor advancing in a phase 2 study. BND-22 enhances the anti-tumor activity of both innate and adaptive immune cells by blocking the interaction between ILT2 and HLA-G, for the treatment of solid tumors.. 除BND-67外,Biond的临床管线还包括BND-22,这是一种首创的抗体,作为靶向ILT2受体的多细胞检查点抑制剂,目前正处于II期临床研究阶段。BND-22通过阻断ILT2与HLA-G之间的相互作用,增强先天性和适应性免疫细胞的抗肿瘤活性,用于实体瘤的治疗。Biond was founded in 2016, by Tehila Ben Moshe, Ph.D., Ori Shilo, and a team of accomplished scientists and drug developers from the Israeli biopharmaceutical industry. Biond 由 Tehila Ben Moshe 博士、Ori Shilo 以及一支来自以色列生物制药行业的杰出科学家和药物研发团队于 2016 年创立。www.biondbio.com www.biondbio.com. 。Company contact: 公司联系人:Tal Sines 塔尔·西内斯VP of Business Development 业务发展副总裁Biond Biologics Ltd. Biond生物制剂有限公司+972-4 884 4337 +972-4 884 4337tal.sines@biondbio.com tal.sines@biondbio.comSOURCE Biond Biologics Ltd. 来源:Biond Biologics Ltd.